Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy for platinum-resistant or platinum-refractory ovarian cancer
ChiCTR2000040055Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Dec 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Beijing Chaoyang Hospital. Primary endpoint: 6-month progression-free interval rate. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2000040055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040055.